

Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer

ANNELIESE FINK-RETTTER¹, DAPHNE GSCHWANTLER-KAULICH¹, GERNOT HUDELIST^{1,4},
RUTH MUELLER^{1,2}, ERNST KUBISTA^{1,3}, KLAUS CZERWENKA² and CHRISTIAN F. SINGER^{1,3,4}

Divisions of ¹Special Gynecology, ²Gynecopathology, ³Ludwig-Boltzmann-Institute of Clinical Experimental Oncology, Medical University of Vienna, 1090 Vienna; ⁴Department of Obstetrics and Gynecology, Villach Medical Center, Vienna, Austria

Received May 16, 2006; Accepted September 26, 2006

Abstract. Overexpression of HER family members is a well established prognostic factor and identifies potential targets for antibody-based receptor blocking strategies. While several studies have analyzed the expression of HER2 and other HER-family members in malignant tumors, considerably less is known about their expression and activation in non-involved breast tissue from breast cancer patients. We have therefore investigated the differential expression of EGFR, HER2, and their tyrosine-kinase activated forms (ptyr-1248 Her-2 and ptyr-845 EGFR) in 63 tumor specimen containing: a) malignant epithelium, b) in non-malignant tissue located at the peritumoral margin, and c) in uninvolved breast tissue obtained from tissue distant from the tumor. Using immunohistochemistry (IHC), we found significantly higher HER2 protein expression levels in malignant epithelium than in marginal and peripheral non-malignant epithelium ($p=1.3 \times 10^{-10}$ Fisher's exact test). Epithelial EGFR expression did not differ between the three tissue types, but stromal EGFR protein was significantly more common in marginal and peripheral tissues when compared to tumor tissues ($p=0.008$, Fisher's exact test). When analyzing activated receptor forms, we found epithelial ptyr-1248 HER2 expression in one tumoral, one marginal and one peripheral sample. We did not observe ptyr-845 EGFR in any of the samples analyzed. We found a significant overall correlation between epithelial and stromal EGFR expression ($r=0.442$; $p<0.0001$; Spearman's Rho), and between stromal EGFR expression and normal tissue type ($r=0.170$; $p<0.02$; Spearman's Rho). Epithelial HER2 expression and normal tissue type ($r=0.492$; $p<0.0001$; Spearman's Rho) were inversely correlated. Taken together, we have observed a differential expression pattern of EGFR, HER2, and activated HER2 that is dependent on the spatial relation to a malignant tumor. Our findings of decreased intratumoral EGFR

expression and the absence of activated EGFR suggests that, in contrast to HER2, EGFR inhibition might not be an ideal target for antibody therapy.

Introduction

The HER-family is comprised of the membrane-bound receptors EGFR, HER2, HER3 and HER4, which all share a high degree of structural homology. The proteins are characterized by an extracellular ligand-binding domain which is responsible for ligand recognition and high affinity binding, a single membrane-spanning region, and a cytoplasmic protein tyrosine kinase domain with phosphorylation-triggered signaling properties. While physiological HER receptor activation is associated with cellular proliferation and differentiation, the amplification and consecutive overexpression of HER2 has been found to play a key role in malignant transformation and promotion of breast cancer.

With the exception of HER2, receptor activation is a result of ligand binding to the extracellular domain of HER receptors, which leads to the formation of both receptor homo- and heterodimers (1). Dimerization, in turn, stimulates the intrinsic tyrosine kinase activity and triggers phosphorylation of specific, C-terminal tyrosine residues within the cytoplasmic domain. The ensuing signal transduction occurs through two distinct pathways: the phosphatidylinositol-3-kinase (PI3K) pathway which leads to activation of protein kinase C and increased intracellular calcium concentration, and the ras protein cascade which leads to activation of the MAP kinase. Both pathways ultimately trigger mitogenic responses (2-4).

A number of studies have investigated the expression of EGFR and HER2 in malignant tumors and have found that the co-expression of the two receptors is associated with resistance to endocrine therapies and poor prognosis (5-9). However, both proteins have also proved to be hopeful targets for receptor blocking antibodies such as trastuzumab (Herceptin®) and gefitinib (Iressa®) in selected malignancies.

While most studies have addressed the expression of HER family members in malignant breast tumors (10-12), HER2 expression has also been described in a variety of epithelial cells. HER-2 protein expression levels in these normal tissues were similar to the levels found in non-amplified breast cancers

Correspondence to: Dr C.F. Singer, Division of Special Gynecology, University of Vienna Medical Center, Waehringer Guertel 18-20, 1090 Vienna, Austria
E-mail: christian.singer@meduniwien.ac.at

Key words: breast cancer, EGFR, HER2, tyrosin kinase activation




Figure 1. Immunohistochemical analysis of malignant (right) and non-malignant (left) breast tissue (obtained from marginal or peripheral breast tissue) using the EGFR [negative in (A), positive in (B)], HER2 [no staining in (C), strong staining in (D)], ptyr-845 EGFR [negative in (E), positive control in (F)], and the ptyr-1248 HER2 [no staining in (G), strong staining in (H)], antibodies as described in Materials and methods. (Positive pEGFR control slide, not part of the tissue array).

and breast cancer cell lines (13). By contrast, several studies also demonstrated a higher level of EGFR expression in normal and benign diseased breast tissue than malignant breast tissue (14-18). This is also in line with one publication which describes higher levels of EGFR in marginal tissue (17).

Nevertheless, relatively little is still known about their presence in marginal and peripheral tissues. More specifically, it is not known, whether there is a differential expression and activity pattern of EGFR/HER-family members dependent on the spatial relation within the involved breast.

We have therefore examined the presence and activation status of EGFR and HER2 in three sets of breast biopsies

from breast cancer patients. Tissues were obtained directly from a malignant tumor, from non-malignant marginal tissue, and from non-malignant peripheral breast tissue located at a distant from a malignant tumor. Protein expression of both receptors and their active (ptyr-1248 and ptyr-845) forms were analyzed by immunohistochemistry, and expression profiles in the three sets were correlated.

Materials and methods

Tissue specimen and patient characteristics. Tissue arrays containing 63 paraffin-embedded sets of tissues obtained



SPANDIDOS PUBLICATIONS Immunohistochemical analysis of EGFR, HER2, pEGFR, pHER2 both in normal, tumoral and marginal tissue and in (epi) and stromal (str) cells of human breast tissue. 0, no expression; +, weak expression; ++, moderate expression; +++, high expression as assessed by the IRS (0, 0-2; +, 3-5; ++, 6-9; +++, 10-12).

Type	Score	HER2EPI (%)	HER2STR (%)	PHER2EPI (%)	PHER2STR (%)	EGFREPI (%)	EGFRSTR (%)	PEGFREPI (%)	PEGFRSTR (%)
Normal	0	52 (100)	65 (100)	34 (97.1)	65 (100)	46 (88.5)	55 (84.6)	53 (100)	65 (100)
	+	0	0	1 (2.9)	0	5 (9.6)	10 (15.4)	0	0
	++	0	0	0	0	1 (1.9)	0	0	0
	+++	0	0	0	0	0	0	0	0
Tumor	0 ^a	40 (62.5)	65 (100)	47 (97.9)	64 (100)	59 (92.2)	63 (98.5)	64 (100)	65 (100)
	+	9 (14)	0	0	0	1 (1.6)	1 (1.5)	0	0
	++	8 (12.5)	0	0	0	2 (3.1)	0	0	0
	+++	7 (11)	0	1 (2.1)	0	2 (3.1)	0	0	0
Margin	0	47 (98)	59 (100)	34 (97.1)	59 (100)	45 (93.8)	54 (91.5)	48 (100)	59 (100)
	+	1 (2)	0	1 (2.9)	0	3 (6.2)	5 (8.5)	0	0
	++	0	0	0	0	0	0	0	0
	+++	0	0	0	0	0	0	0	0

directly from the malignant tumor ('tumor'), from microscopically uninvolved tissue <15 mm distant from the invasive front of a malignant tumor ('margin'), and from peripheral breast tissue ('peripheral') were purchased from Biomax (Biomax Inc., Rockville, MD). The presence or absence of malignant tumor cells and of epithelial cells was confirmed by an experienced pathologist of our department. The patients had a mean age of 51.5 years (range 31-72 years) and 59 of the 63 were post-menopausal (94%). Of the 63 tumor-derived specimens 57 contained tumor cells and were comprised of 41 invasive-ductal, 1 invasive-lobular, 2 medullary, 1 mucinous carcinoma, 10 NOS, 1 ductal carcinoma *in situ* and 1 cysto-sarcoma phylloides of the breast. Forty-five of 63 cases (70%) were estrogen receptor positive.

Immunohistochemistry. Immunohistochemical HER2 protein expression was assessed by utilizing the Herceptest[®] according to the manufacturer's recommendations (Dako, Glostrup, Denmark). Expression of EGFR protein was assessed by using the EGFR PharmDX[®] kit according to the manufacturer's recommendations (Dako). The phosphorylated forms of HER2 and EGFR (ptyr-1248 HER2 and ptyr-845 EGFR) were immunodetected with the monoclonal antibodies PN2A (anti-ptyr-1248 HER2, Dako) and EGFR-12A3 (anti-ptyr-845 EGFR, Nanotools, Munich, Germany) as previously described (7,19). The sensitivity and specificity of EGFR-12A3 has been described previously (20). In brief, paraffin-embedded sections were deparaffinized, tissues were rehydrated, and antigen retrieval was performed by microwaving sections in 10 mmol/l citrate buffer (pH 6.0) for 15 min. Slides were then washed with PBS, blocked with Ultra V Block (Lab Vision, Fremont, CA), and incubated with the primary antibodies at a dilution of 1:30 at 4°C overnight. Sections were sequentially incubated with biotinylated goat anti-polyvalent (Lab Vision) and

streptavidin-HRP (Lab Vision) at RT for 30 min, and the immunoreaction was visualized with 3-amino-9-ethylcarbazole (AEC, Sigma). EGF-treated and thus ptyr-1248 HER2, ptyr-845 EGFR and ptyr-173 EGFR positive cells were used as controls. The specificity of both phosphoantibodies has been confirmed previously (19).

HER2 overexpressing SKBR3 human mammary carcinoma cells were stimulated with 100 ng/ml to achieve receptor phosphorylation at the tyr-1248 HER2 site and were used as positive controls for ptyr-1248 HER2 as previously described (21). One hundred ng/ml EGF-stimulated human epithelial A-431 carcinoma cells were used as positive controls for ptyr-845 EGFR (data not shown) (7,19). Expression of both receptors and their phosphorylated forms was assessed using the HercepScore[®] according to the manufacturer's recommendations (Dako) and only membrane-specific staining was considered positive. Staining was independently assessed by two experienced pathologists of our department. Representative photomicrographs of immunohistochemical analysis are shown in Fig. 1.

Statistical analysis. Fisher's exact test was used to identify significant differences in receptor protein expressions in tumoral, marginal, and peripheral biopsies of total and activated HER2 and EGFR. Associations between protein expression of the investigated receptors were evaluated by Spearman's Rho test. SAS statistical software system (SAS Inc., Cary, NC, version 8.1) was used for all calculations and a two-sided p-value of <0.05 was considered statistically significant.

Results

Fig. 1 and Table I show the expression of EGFR, HER2, ptyr-845 EGFR and ptyr-1248 HER2 in tumoral, marginal and peripheral breast tissue as measured by immunohisto-

Table II. Correlation coefficient (r) and p-value between EGFREPI (epithel), EGFRSTR (stroma), HER2EPI (epithel), HER2STR (stroma) and HISTO (malignant vs non-malignant breast tissue).

	EGFREPI	EGFRSTR	HER2EPI	HER2STR	HISTO
EGFREPI	1	r=0.442 p<0.0001	r=-0.056 p=0.49	- -	r=0.055 p=0.49
EGFRSTR	-	1 -	r=-0.124 p=0.11	- -	r=0.170 p<0.02
HER2EPI	-	-	1 -	- -	r=-0.491 p<0.0001
HER2STR	-	- -	- -	1 -	- -

chemical analysis. When present, receptor staining was exclusively found in the cell membranes, regardless of the antibody used (Fig. 1). A strong epithelial HER2 expression was found in 7 tumor samples (11%), while intermediate expression was observed in 8 (12.5%), and weak expression was seen in 9 (14%) cases of the 64 tumor tissues investigated. By contrast, none of the 52 normal epithelial tissues expressed HER2, and only one of the 48 tissues obtained from the tumoral margin exhibited weak HER2 expression (2%). Furthermore, none of the stromal cells stained for HER2, regardless of their relation to a malignant tumor (Table I). When the activated form of HER2 was analyzed in the same tissue samples, we found one case of high epithelial pHER2 expression in tumoral tissue (2.1%), as well one case of weak expression in normal and marginal epithelium each (2.9 and 2.9%, respectively). Epithelial EGFR was found in 5 of 64 tumor samples (7.8%), while 6 of the normal breast biopsies (11.5%) and 3 of the marginal samples (6.2%) expressed the protein. The stromal EGFR expression was observed in only one of the 64 tumor samples (1.5%) while in normal tissues we found EGFR expression in 10 of 65 cases (15.4%) and in marginal tissue in 5 of 59 cases (8.5%). We did not observe any pEGFR staining, regardless of cell type and sample. We did not observe HER2 or EGFR staining in the cystosarcoma phyllodes case (Table I).

When the presence of EGFR, HER2 and their activated forms was compared in tumor, marginal and peripheral tissue, we found that HER2 expression in malignant epithelium was significantly more common than in normal ductal epithelium (0/52; $p=6.2 \times 10^{-6}$, Fisher's exact test), and as well as in epithelium obtained from the tumor margin (1/47; $p<0.00001$, Fisher's exact test).

While there was no difference in the epithelial pHER2 expression, and in the epithelial EGFR expression in benign and malignant tissues ($p=n.s.$ and $p=n.s.$, respectively), stromal EGFR was significantly more common in normal tissue when compared to tumor samples ($p=0.008$, Fisher's exact test).

Correlations. We then looked at possible correlations between the different parameters (Table II). We found a significant overall correlation between stromal EGFR expression and normal tissue ($r=0.170$; $p<0.02$; Spearman's Rho), and between

epithelial and stromal EGFR expression ($r=0.442$; $p<0.0001$; Spearman's Rho). Epithelial HER2 expression was inversely correlated with normal tissue ($r=0.491$; $p<0.0001$; Spearman's Rho).

Discussion

Co-expression of HER2 and EGFR has been observed in 7-8% of malignant breast tumors and has been shown to be associated with shorter DFS and OS in patients with early and advanced breast cancer (6,7,16). While most studies have concentrated on intratumoral receptor expression little is known about peritumoral expression in surrounding, histologically uninvolved tissue. We present herein the first systematic study which investigates the spatial expression of EGFR, HER2 and their activated forms in tumoral, marginal, a peripheral breast tissue from breast cancer patients. Our finding of intratumoral HER2 and pHER2 expression supports a wealth of previous studies, in which the receptor was observed in 10-40% of human early breast cancers (22) and its activated form in 3-5% (23,24). We have, however, also detected overexpression of HER2 in histologically normal breast epithelium from the vicinity of a malignant tumor. A small constitutive amount of HER2 expression in normal breast tissue is consistent with reports described (13), but the HER2 expression in marginal breast tissue has not been reported previously. In contrast to normal breast tissue in benign tumors, especially in fibroadenomas, the HER2 expression is discussed controversially (25,26).

Similar to HER2, EGFR expression in human breast carcinomas has also been associated with an unfavourable prognosis (27-32) but the incidence of EGFR expression in breast cancer reported varies between 14-65% (33). However, it has been widely reported that EGFR is expressed more frequently in non-malignant than malignant breast tissues (15,16,33,34). EGFR expression can be observed in a variety of normal cells including many epithelial cell types (35,36-41). Non-epithelial cell types that express EGFR include smooth muscle cells, fibroblasts, and perineurium (42).

In our study, epithelial EGFR expression did not differ between normal, tumor and marginal tissue, whereas stromal EGFR was significantly more common in marginal and peri-



ue than in the actual tumor samples ($p=0.008$, Fisher's). Our results are somewhat contradicted by findings from Möller *et al*, who did not find EGFR positive stromal cells in normal breast tissue but in fibroadenomas stroma (25%). This group did, however show EGFR positive epithelial cells in the close vicinity of malignant tumor samples of the breast while stroma remained negative (43). Similar findings were published by others (16,44,45).

There is no previous information on the activity of EGFR in the general population of breast cancer patients. While we were unable to observe activated EGFR in any of the tissues investigated, Gschwantler *et al* found in a highly selected patient population, HER2 overexpressing malignant breast tumors, an EGFR expression in 35% and activated EGFR expression in 13% of cases (19). Hudelist *et al* showed in this patient population that the presence of pHER2 and pEGFR was a strong predictor of both response to trastuzumab-based treatment and clinical benefit (20). EGFR expression and activated EGFR expression was investigated also in other tissue types: in node-positive colorectal cancer patients Cunningham *et al* found that EGFR was expressed in 76% of the cases and pEGFR was positive in 8% (46). In untreated non-small cell lung cancer (NSCLC) the expression rate of EGFR, pEGFR and HER2 was 97.2, 44.4 and 86.1%, respectively and the overexpression rate was 80.6, 0.0 and 27.8%. They demonstrated that neither overexpression of EGFR nor HER2 correlated with the time to progression or overall survival, while EGFR phosphorylation showed an inverse correlation with regard to time to progression and overall survival in the patients with NSCLC. These results suggest that the phosphorylation of EGFR might be an important predictor for clinical outcome of NSCLCs, possibly due to variant III mutations within the TK domain of the EGFR, which might be responsible for the higher response rate following treatment with EGFR inhibitors (47).

The success of TK inhibitors in NSCLCs is in striking contrast to results from several studies which have analyzed the activity of TK inhibitors in metastatic breast cancers: while some of these studies demonstrate modest single-agent activity, they are somewhat disappointing, presumably because until now, activating EGFR mutations have not been described in breast cancer, and because EGFR signaling does not seem to be critically involved in local invasion and tumor progression (48; Albain K, *et al*, Breast Cancer Res Treat 76: 33, abs. 20, 2002; Robertson JFR, *et al*, Proc Annu Meet Am Soc Clin Oncol 22: 7, abs. 23, 2003; Baselga J, *et al*, Proc Annu Meet Am Soc Clin Oncol 22: 7, abs. 24, 2003).

In conclusion, we report herein for the first time the differential expression pattern of EGFR, HER2 and their activated forms depending on the spatial relation to a malignant tumor. The fact that intratumoral EGFR expression is decreased in comparison to peritumoral expression, and the lack of activated EGFR in any of the samples suggests that, in contrast to HER2, EGFR inhibition might not be an ideal target for antibody therapy. The topic of EGFR mutations is clearly an interesting and important one, and further research should be undertaken in the general population of breast cancer patients.

Acknowledgements

Supported by the Medizinisch-Wissenschaftlicher Fonds des Buergermeisters der Bundeshauptstadt Wien, by the Ludwig Boltzmann Society for Clinical Experimental Oncology, and by a grant from Amgen.

References

- Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. *EMBO J* 19: 3159-3167, 2000.
- Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. *Biochem Biophys Res Commun* 319: 1-11, 2004.
- Zabrecky JR, Lam T, McKenzie SJ and Carney W: The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. *J Biol Chem* 266: 1716-1720, 1991.
- Normanno N, Ciardiello F, Brandt R and Salomon DS: Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. *Breast Cancer Res Treat* 29: 11-27, 1994.
- Camp ER, Summy J, Bauer TW, Liu W, Gallick GE and Ellis LM: Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. *Clin Cancer Res* 11: 397-405, 2005.
- Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J and Hachitanda Y: Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. *Surgery* 133: 219-221, 2003.
- Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E and Czerwenka K: Co-expression of ErbB-family members in human breast cancer: HER-2 is the preferred dimerization candidate in nodal-positive tumors. *Breast Cancer Res Treat* 80: 353-361, 2003.
- Harris AL, Nicholson S, Sainsbury JR, Farndon J and Wright C: Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. *J Steroid Biochem* 34: 123-131, 1989.
- Ogura H, Akiyama F, Kasumi F, Kazui T and Sakamoto G: Evaluation of HER-2/status in breast carcinoma by fluorescence *in situ* hybridization and immunohistochemistry. *Breast Cancer* 10: 234-240, 2003.
- Witton CJ, Reeves JR, Going JJ, Cooke TG and Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. *J Pathol* 200: 290-297, 2003.
- Tsutsui S, Ohno S, Murakami S, Hachitanda Y and Oda S: Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. *Br Cancer Res Treat* 71: 67-75, 2002.
- Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E and Nesland JM: EGFR family expression in breast carcinomas. C-erb-2 and c-erbB-4 receptors have different effects on survival. *J Pathol* 196: 17-25, 2002.
- Press MF, Cordon-Cardo C and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. *Oncogene* 5: 953-962, 1990.
- Koenders P, Faverly D, Beex L, Bruggink E, Kienhuis CS and Benraad T: Epidermal growth factor receptors in human breast cancer: a plea for standardization of assay methodology. *Eur J Cancer* 28: 693-697, 1992.
- Travers M, Barrett-Lee P, Berger U, Lugmani Y, Gazet J, Powles T and Coombes R: Growth factor expression in normal, benign and malignant breast tissue. *Br Med J* 296: 1621-1624, 1988.
- Robertson KW, Reeves JR, Smith G, *et al*: Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. *Cancer Res* 56: 3823-3830, 1996.
- Dittadi R, Donisi P, Brazzale A, Cappellozza L, Bruscagnin G and Gion M: Epidermal growth factor receptor in breast cancer. Comparison with non-malignant breast tissue. *Br J Cancer* 67: 7-9, 1993.
- Mansouri OA, Zekri AR, Harvey J and El-Ahmady O: Epidermal growth factor receptors: status and effect on breast cancer patients. *Anticancer Res* 17: 3107-3110, 1997.
- Gschwantler-Kaulich D, Hudelist G, Koestler WJ, Czerwenka K, Mueller R, Helmy S, Ruecklinger E, Kubist E and Singer CF: EGFR activity in Her-2 over-expressing metastatic breast cancer: evidence for simultaneous phosphorylation of HER-2 and EGFR. *Oncol Rep* 14: 305-311, 2005.

20. Hudelist G, Kostler WJ, Czerwenka K, Kubista E, Attems J, Muller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschutsky H, Zielinski CC and Singer CF: Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. *Int J Cancer* 118: 1126-1134, 2005.
21. Hudelist G, Kostler WJ, Attems J, Czerwenka K, Muller R, Manavi M, Steger GG, Kubista E, Zielinski CC and Singer CF: Her-2/neu-triggered intracellular tyrosine kinase activation: *in vivo* relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. *Br J Cancer* 89: 983-991, 2003.
22. Hynes NE and Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. *Biochim Biophys Acta* 1198: 165-184, 1994.
23. Thor AD, Edgerton S, Moore D, Kasowitz KM, Benz CC, Stern DF and Di Giovanna MP: Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. *J Clin Oncol* 18: 3230-3239, 2000.
24. Di Giovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D and Thor AD: Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. *J Clin Oncol* 23: 1152-1160, 2005.
25. Suo Z, Emilsen E, Tveit KM and Nesland JM: Type 1 protein tyrosine kinases in benign and malignant breast lesions. *Histopathology* 33: 514-521, 1998.
26. Tauchi K, Hori S, Itoh H, Yoshiyuki Osamura R, Tokuda Y and Tajima T: Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. *Virchows Archiv A Pathol Anat* 416: 65-73, 1989.
27. Nicholson S, Wright C, Sainsbury JR, *et al*: Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node negative breast cancer patients: new and tamoxifen failure. *J Steroid Biochem Mol Biol* 37: 811-814, 1990.
28. Nicholson S, Halcrow P, Sainsbury JR, *et al*: Epidermal growth factor receptor (EGFr) status associated with failure of primary endocrine therapy in elderly post-menopausal patients with breast cancer. *Br J Cancer* 58: 810-814, 1988.
29. Hainsworth PJ, Henderson MA, Stillwell RG and Bennett RC: Comparison of EGFR, c-erbB-2 product and ras p21 immunohistochemistry as prognostic markers in primary breast cancer. *Eur J Surg Oncol* 17: 9-15, 1991.
30. Nicholson S, Richard J, Sainsbury C, *et al*: Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. *Br J Cancer* 63: 146-150, 1991.
31. Railo MJ, Smitten KV and Pekonen F: The prognostic value of epidermal growth factor receptor (EGFR) in breast cancer patients. Results of a follow-up study on 149 patients. *Acta Oncol* 33: 13-17, 1994.
32. Koutselini H, Markopoulos C, Lambropoulou S, Gogas H, Kandaraki C and Gogas J: Relationship of epidermal growth factor receptor (EGFR); proliferating cell nuclear antigen (PCNA) and vimentin expression and various prognostic factors in breast cancer patients. *Cytopathology* 6: 14-21, 1995.
33. Klijn J, Berns P, Schmitz P and Foekens J: The clinical significance of epidermal growth factor receptor in human breast cancer: a review on 5232 patients. *Endocrine Rev* 13: 3-17, 1992.
34. Jensen EV: Hormone dependency of breast cancer. *Cancer* 47: 2319-2326, 1981.
35. Sainsbury JR, Farndon JR, Sherbet GV and Harris AL: Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. *Lancet* 1: 364-366, 1985.
36. Coussens L, Yang-Fenkg TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A and Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. *Science* 230: 1132-1139, 1985.
37. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Satio T and Toyoshima K: Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. *Nature* 319: 230-234, 1986.
38. Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A and Coussens L: The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. *Science* 229: 976, 1985.
39. Gusterson B, Cowley G, Smith JA and Ozanne B: Cellular localisation of human epidermal growth factor receptor. *Cell Biol Int Rep* 8: 649-658, 1984.
40. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. *Br Med Bull* 47: 87, 1991.
41. Ozanne B, Richards CS, Hendler F, Burns D and Gusterson B: Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. *J Pathol* 149: 9-14, 1986.
42. Werner MH, Nanney LB, Stoscheck CM and King LE: Localization of immunoreactive epidermal growth factor receptors in human nervous system. *J Histochem Cytochem* 36: 81-86, 1988.
43. Möller P, Mechttersheimer G, Kaufmann M, Moldenhauer G, Momburg F, Mattfeldt T and Otto HF: Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast. *Virchows Arch A Pathol Anat* 414: 157-164, 1989.
44. Barker S, Panahy C, Puddefoot JR, Goode AW and Vinson GP: Epidermal growth factor receptor and oestrogen receptors in the non-malignant part of the cancerous breast. *Br J Cancer* 60: 637-677, 1989.
45. Ozawa S, Ueda M, Ando N, Abe O and Shimizu N: Epidermal growth factor receptors in cancer tissues of esophagus, lung, pancreas, colorectum, breast and stomach. *Jpn J Cancer Res* 79: 1201-1207, 1988.
46. Cunningham MP, Essapen S, Thomas H, Green M, Lovell DP, Topham C, Marks C and Modjtahedi H: Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. *Int J Oncol* 27: 317-327, 2005.
47. Chan SK, Gullick WJ and Hill ME: Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. *Eur J Cancer* 42: 17-23, 2006.
48. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M and Chen B: EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER2 status and absence of EGFR-activating mutations. *Mod Pathol* 18: 1027-1033, 2005.